The leading Italian pharmaceutical company Angelini ACRAF S.p.A. has recently started the promotion, marketing and distribution of a new active wound cleanser, under its own brand, in Italian hospitals and wound therapy centers.
The product has been acquired based on an exclusive partnership between Angelini and APR Applied Pharma Research, the owner and developer of the proprietary, patented technology TEHCLO®, which enables the production of this acidic and super-oxidizing solution.
The innovative acid-oxidizing solution contains hypoclorous acid and is indicated for the treatment of chronic wounds (e.g. diabetic foot ulcers, pressure ulcers, lower leg ulcers, vascular ulcers), post-surgical wounds, cuts, abrasions, burns and other lesions. As it contains hypochlorous acid as a preservative, it can prevent wound contamination by exerting a local antimicrobial effect on the wound surface.
In the field of Wound Care, Angelini is now able to provide healthcare professionals with a range of wound treatment options from active cleansing, to antisepsis and epithelialization support.
Thanks to this launch, Angelini strengthens its position in the Wound Care therapeutic area fulfilling a medical need of the scientific community, which encompasses the shift from a passive method of mere cleansing to an active process supporting the physiological healing process.
“We are very proud to see this product on the Italian market“ said Mr. Galfetti, CEO of APR. “as it represents a new and unique option to actively cleanse any kind of wound. We believe that this product, for its adaptable use along the continuum of wound care, offers the opportunity to exploit the growth forecasted in the wound cleansing market on an European basis, which is expected to hit a total value of $220 Mio in 2019.”